Results 11 to 20 of about 2,190 (132)
Biochemical Abnormality of DNA Synthesis of Erythroblasts in Acute and Chronic Myeloid Leukemia [PDF]
Blood, 1973 Abstract Six patients with acute and chronic myeloid leukemia (AML and CML) showed a low incorporation of labeled DNA precursors into basophilic erythroblasts. Based on mitotic indices and the use of vincristine as a stathmokinetic tool, it was evident that brisk proliferation in this cell compartment took place.
P, Ernst, M, Baccarani, S A, Killmann
openaire +2 more sources
Acute erythroid leukemia: autopsy report of a rare disease
Autopsy and Case Reports, 2011 Acute erythroid leukemia (AEL) is a rare subtype of acute myeloid leukemia (AML), characterized by predominant erythroid proliferation. The 2008 World Health Organization (WHO) classification of AML defined two AEL subtypes: erythroleukaemia (EL), in ...
Cristiane Rúbia Ferreira +6 more
doaj +1 more source
GRAVIS MYASTHENIA – ACUTE ERYTHROBLASTIC LEUKEMIA CORRELATION
Romanian Medical Journal, 2017 Myasthenia Gravis is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. It occurs in all races, at any age (especially under 40 or over 60), both genders, with a prevalence of 20/100,000 population in the United States.
Angela Mirela Soare, Cezar Mihai Popescu
openaire +1 more source
Autopsy findings of acute erythroid leukemia
Autopsy and Case Reports, 2023 Acute erythroid leukemia (AEL) is an exceedingly uncommon but distinct hematological malignancy that shows neoplastic proliferation of erythroid precursors with maturation arrest and no significant myeloblasts.
Mayur Parkhi +6 more
doaj
Coronary Microvascular Dysfunction: Epidemiology, Pathophysiology, Diagnosis, and Treatment
MedComm, Volume 7, Issue 8, August 2026.This visual summary illustrates the key aspects of coronary microvascular dysfunction (CMD) in angina with nonobstructive coronary artery disease (NOCAD), including epidemiology, pathophysiology (microvascular remodeling and endothelial dysfunction), the protective NRG‐1/ErbB signaling pathway, diagnostic methods, and both Western and traditional ...
Zhao Ge +8 more
wiley +1 more source
Genetic analysis of primary lung interdigitating dendritic cell sarcomas
The Journal of Pathology, Volume 269, Issue 4-5, Page 387-398, August 2026.Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov +6 more
wiley +1 more source
Journal of Cellular and Molecular Medicine, Volume 30, Issue 14, July 2026.ABSTRACT Erythroblastic sarcoma is a rare and aggressive hematologic malignancy presenting as a mass‐forming extramedullary proliferation of immature erythroid cells. Myeloid/lymphoid neoplasms with JAK2 rearrangement, most often PCM1::JAK2, may show eosinophilia, myelofibrosis, and expansion of immature erythroid precursors.
Tong Ge +6 more
wiley +1 more source
Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases
MedComm, Volume 7, Issue 4, April 2026.Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang +3 more
wiley +1 more source
The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
MedComm, Volume 7, Issue 1, January 2026.Monocytes infiltrate the tumor microenvironment (TME) and differentiate into macrophages, which polarize into proinflammatory, antitumor M1 cells or immunosuppressive, protumor M2 cells. Within the TME, M2‐type tumor‐associated macrophages (TAMs) predominate and drive tumor growth, angiogenesis, and metastasis. Therapeutic strategies therefore focus on
Zhimei Liu +5 more
wiley +1 more source
BioMed Research International, Volume 2026, Issue 1, 2026.The cross‐reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, “one warhead–one target”, modulators. On the other hand, the potential “impasse” fuels repurposing of already developed drugs.
Monika I. Konaklieva +2 more
wiley +1 more source